Floatz logo

Irinotecan

Unresectable Digestive System Neuroendocrine Carcinoma

Roswell Park Cancer InstituteSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

50 Active assets in the Unresectable Digestive System Neuroendocrine Carcinoma cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
National Cancer Institute (NCI)
Phase 2BB
CIS-DIAMMINEDICHLOROPLATINUM II
National Cancer Institute (NCI)
Phase 2B
Everolimus
AIO-Studien-gGmbH
Phase 2B
Tarlatamab
National Cancer Institute (NCI)
Phase 2B
Carboplatin
Phanes Therapeutics
Phase 2B

View all 50 →

Same molecule, other indications

Irinotecan is also rated in:

rectal cancerDormant
BBB
Indicative ·
78 / 100
View asset →
exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
Peritoneal NeoplasmsDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →